Day: June 3, 2020

Dallas, Texas, June 03, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NaturalShrimp today issued this letter to its shareholders.Dear Fellow Shareholders:As we previously announced in the April 29, 2020 Press Release, the Company and the insurance company have been waiting on the final Fire Marshal’s report that has not been published as of this week. Upon receipt, the Company will post the report on its website: https://naturalshrimp.com. We are excited about all the positive developments for our Company’s strategic direction. This event did not destroy our technology or the tremendous business opportunity it provides. It simply delayed our timeline.The Company’s insurance company, General Star Indemnity Company, has settled and paid in full 100% of our claims which will be more than $917,000. We are happy to announce the Company...

NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate and host one-on-one meetings at two virtual investor conferences in June.Details are as follows:The Company’s BIO Digital presentation will be made through the BIO Digital website and available on demand to registered participants during the conference at https://www.bio.org/events/bio-digital/sessions/691517.A live webcast and subsequent archived recording of the Company’s presentation at the Virtual Summer Summit will be available under the IR Events tab of the Investor Relations section of the Tonix website at www.tonixpharma.com.About Tonix Pharmaceuticals Holding Corp.Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing,...

AMRYT PHARMA PLC(“Amryt” or the “Company”)AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE (“CEE”)Amryt, a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces the signing of a distribution agreement with Swixx BioPharma AG (“Swixx”) of Baar, Switzerland. Under the agreement, Amryt has appointed Swixx as exclusive distributor of  Myalepta® (metreleptin) in the EU territories of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia. In addition, Swixx will distribute Myalepta® for Amryt in the West Balkan countries of Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North...

IRVINE, Calif., June 03, 2020 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of intelligent edge and secure data management solutions for the Industrial Internet of Things (IoT), today announced that its xPico 250 IoT gateway is being used by Tangen Biosciences in the development of its rapid and sensitive molecular diagnostic test for detection of SARS-CoV-2, the causative agent for COVID-19. “Lantronix’s xPico 250 IoT gateway gave us the small, secure multi-protocol connectivity solution we needed for our GeneSparkTM analyzer on which our COVID-19 molecular assay will be running,” said Ting Yi, Ph.D., MBA and Director of Business Development for Tangen Biosciences Inc. “With the xPico 250, we will be able to accelerate the timeline to deliver the GeneSpark design in compliance with the FDA’s Emergency Use...

DENVER, CO, June 03, 2020 (GLOBE NEWSWIRE) — Intrepid Potash Inc. (NYSE:IPI) (“Intrepid”) today announced that on June 2, 2020 it received written notice from the New York Stock Exchange (“NYSE”)  stating that Intrepid had regained compliance with the applicable NYSE minimum share price requirement.On April 17, 2020, Intrepid previously received notice from the NYSE that its stock price had fallen out of compliance with NYSE continued listing standards. Under NYSE listing standards, Intrepid could regain compliance at any time during the original 6 month cure period if its common stock had a closing price of at least $1.00 per share on the last trading day of any calendar month during the cure period and an average closing price of at least $1.00 per share of common stock over the 30-trading-day period ending on the last trading...

Multiple Complete Responses Observed in Advanced Cutaneous Squamous Cell CarcinomaHigh Rate of Deep Responses in Anti-PD-1 / Anti-CTLA-4 Refractory MelanomaAnnounces Intention to Commence Clinical Development in Anti-PD-1 Refractory Non-Small Cell Lung CancerWOBURN, Mass., June 03, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced new interim data presented from the Phase 2 part of its Phase 1/2 clinical trial of RP1 in combination with Opdivo® that continues to provide strong support for its lead indications of cutaneous squamous cell carcinoma (CSCC) and anti-PD-1 refractory melanoma.“CSCC is a significant commercial opportunity that we believe has the potential to drive substantial value for the company....

NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 9:40 a.m. ET. The conference will be held in a virtual meeting format.Webcast information for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast.About Applied Therapeutics Inc.Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against...

OTTAWA, June 03, 2020 (GLOBE NEWSWIRE) — HEXO Corp (“HEXO”, or the “Company”) (TSX: HEXO; NYSE: HEXO) is proud to launch new 30 gram medical flower format for its popular high-THC strain Tsunami under HEXO medical cannabis.HEXO has been dedicated to providing Canadian clients high quality medical cannabis since 2015. A year ago, the Company updated its medical packaging to comply with the Cannabis Regulations, resulting in smaller product formats.  HEXO is proud to launch a new 30 g format offered in a resealable, odour-proof and child-resistant pouch.“We know our medical clients have been waiting for this opportunity to purchase a higher volume of cannabis without excess packaging,” said HEXO CEO and co-founder Sebastien St-Louis. “Our Tsunami flower benefits from enhanced humidity controls for maximum freshness and to promote...

OTTAWA, 03 juin 2020 (GLOBE NEWSWIRE) — HEXO Corp (« HEXO », ou la « Société ») (TSX : HEXO ; NYSE : HEXO) annonce avec fierté le lancement, sous la division HEXO cannabis médical, d’un nouveau format de 30 grammes de fleurs de sa populaire souche Tsunami à haute teneur en THC. Depuis 2015, HEXO vise à fournir du cannabis médical de haute qualité aux clients canadiens. Il y a un an, la Société a modifié son emballage médical pour se conformer à la réglementation sur le cannabis, entraînant une réduction des formats de produits.  HEXO est fière de lancer un nouveau format de 30 g présenté dans un sachet refermable, étanche aux odeurs et à l’épreuve des enfants.« Nous savons que nos clients médicaux attendaient cette opportunité pour acheter un plus grand volume de cannabis sans emballage excessif », a déclaré Sébastien St-Louis,...

BEIJING, June 03, 2020 (GLOBE NEWSWIRE) — Secoo Holding Limited (NASDAQ:  SECO) (together with its affiliates, “Secoo”), Asia’s largest online integrated upscale products and services platform, and Qudian, Inc. (NYSE:  QD) (together with its affiliates, “Qudian”), a leading technology platform empowering the enhancement of online consumer finance experience in China, announced today that Secoo and Qudian have entered into a definitive agreement, pursuant to which Qudian has agreed to purchase a total of up to 10,204,082 newly issued Class A ordinary shares of Secoo for an aggregate purchase price of up to US$100,000,003.60, reflecting a per share purchase price of US$9.80.Following the completion of all transactions contemplated under the definitive agreement, Qudian will hold approximately 28.9% of Secoo’s issued and outstanding...